GCV Asia Congress 2017
Skip Content

15 February 2017

Mark Turco innovates at Penn Center

Pennsylvania University’s Penn Center for Innovation has appointed Mark Turco as chief innovation corporate outreach officer, hiring him from Medtronic.

Author: Thierry Heles, editor

Mark Turco (pictured) has joined Pennsylvania University (UPenn)’s commercialisation arm Penn Center for Innovation (PCI) as its new chief innovation and corporate outreach officer.

Turco previously served as vice-president and chief medical officer of the aortic, peripheral, vascular and endovenous franchises of healthcare company Medtronic.

At PCI, Turco will be responsible for building relationships with external partners as part of UPenn’s efforts to increase commercialisation activities regionally, nationally and across the globe.

John Swartley, assistant vice-provost for research and managing director of PCI, said:  “Mark’s prior accomplishments and background in both the medical field and the private and public sectors are of tremendous value to our organisation, and he brings a unique perspective to PCI and our executive leadership team.

“I am really delighted to welcome Mark on board, and we are all looking forward to working closely with him to build additional strategic relationships between the Penn community and industry to help better connect our faculty with corporate and other possible partners.”

Mark Turco said: “I am looking forward to working with Penn’s expert faculty and other members of its innovation community as well as external partners to facilitate and extend new and ongoing collaborations to translate Penn ideas into products and services that benefit patients and society.

“I am truly excited to bring my skills and experience as a physician, scientist and business development leader to further support and extend the university’s innovation and commercialisation goals.”

– Image courtesy of LinkedIn

Copyright Mawsonia Limited 2010. Please don´t cut articles from www.globaluniversityventuring.com or the PDF and redistribute by email or post to the web without written permission.

  • Linkedin
  • Mail
  • Rssfeed